The phenotype of IIH headache appears to mirror that of episodic and chronic migraine [
9] and increasingly off-label migraine treatment is used in IIH patients to treat headache without any formal evidence of efficacy [
2]. Overuse of simple analgesics, opiates, and non-steroidal anti-inflammatory drugs is common in IIH and may result in medication-overuse headache [
61,
62]. Patients who achieve 10–15% weight loss often see an improvement in their headache [
46], although sometimes this can only be achieved with bariatric surgery [
63]. Although therapeutic LP may reduce headache in the short term, repeated LPs are not recommended as they may result in complications such as intracranial hypotension [
64,
65]. Headache generation and pain are thought to be due to peripheral sensitisation of the trigeminovascular system, in which innervation of the dura by nociceptive trigeminal fibers, leads to release of vasoactive neuropeptides including calcitonin gene-related peptide (CGRP) and substance P [
66‐
68]. In the case of migraine, repeated periods of sensitisation over time is thought to cause a decrease in nociceptive threshold and may result in chronicity [
69]. CGRP is thought to play an important role in the pathogenesis of migraine. Plasma CGRP is elevated during migraine attacks and administration of exogenous CGRP may induce migraine without aura in sufferers. Recent trials also demonstrate that monoclonal antibodies against CGRP or the CGRP receptor are effective for the treatment of chronic and episodic migraine [
59,
70‐
75]. Evidence of CGRP involvement in post-traumatic headache, [
76,
77] which also features raised ICP, suggests that these therapeutics would also be effective for IIH headache. Furthermore, the headache phenotype in IIH is typically migraine [
60]. At present, there is no trial evidence for the use of CGRP monoclonal antibodies to treat headaches with a migrainous phenotype in IIH.